Stock Events

Stock Events

Palisade Bio 

€0
65
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Mar 2
€195,315.12
Dec 1
€177,559.2
Sep 1
€177,559.2
Jun 1
€177,559.2
Mar 1
€177,559.2
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-3.16
-2.12
-1.07
-0.03
Expected EPS
-0.0328933488
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-27.39MNet Income

Analyst Ratings

$7.97Average Price Target
The highest estimate is 18.97.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7NS0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, potentially overlapping with Palisade Bio's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences competes in the biopharmaceutical space, focusing on life-threatening diseases, similar to Palisade Bio's focus areas.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech company that develops innovative therapeutics, competing with Palisade Bio in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of pharmaceutical products, directly competing with Palisade Bio's business model.
Biogen
BIIB
Mkt Cap26.03B
Biogen competes with Palisade Bio in the biotechnology and pharmaceuticals sector, focusing on serious diseases.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie operates in the same biopharmaceutical field as Palisade Bio, developing therapies for complex and serious diseases.
Merck
MRK
Mkt Cap298.84B
Merck & Co. is a global healthcare company that produces pharmaceuticals competitive with Palisade Bio's product pipeline.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a direct competitor in the pharmaceuticals sector, with a broad range of products that could compete with Palisade Bio's developments.
Novartis
NVS
Mkt Cap297.32B
Novartis is a global healthcare company with a diverse portfolio, including innovative medicines that could compete with Palisade Bio.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, competing with Palisade Bio in several therapeutic areas.

About

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Show more...
CEO
ISIN
US6963894026
WKN
000A4098S

Listings

MU
DE
7NS0.MU
STU
DE
7NS0.STU
F
DE
7NS0.F
XNAS
US
PALI

0 Comments

Share your thoughts

FAQ

What is Palisade Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Palisade Bio stocks are traded under the ticker 7NS0.F.
When is the next Palisade Bio earnings date?▼
Palisade Bio is going to release the next earnings report on May 12, 2026.
What were Palisade Bio earnings last quarter?▼
7NS0.F earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.03 EUR resulting in a -11.11% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Palisade Bio revenue for the last year?▼
Palisade Bio revenue for the last year amounts to 0 EUR.
What is Palisade Bio net income for the last year?▼
7NS0.F net income for the last year is -27.39M EUR.
Does Palisade Bio pay dividends?▼
Yes, 7NS0.F dividends are paid quarterly. The last dividend per share was 195,315.12 EUR. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Palisade Bio located?▼
Palisade Bio operates in the Other sector.
When did Palisade Bio complete a stock split?▼
The last stock split for Palisade Bio was on April 08, 2024 with a ratio of 1:15.